🇺🇸 FDA
Patent

US 7317023

Diaryl ether β2 adrenergic receptor agonists

granted A61PA61P11/00A61P11/06

Quick answer

US patent 7317023 (Diaryl ether β2 adrenergic receptor agonists) held by Theravance, Inc. expires Mon Jan 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Jan 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61P, A61P11/00, A61P11/06, A61P15/06, A61P25/00